Skip to main content
SpringerLink
Log in

Pharmacological Treatment of Vertigo

  • Therapy In Practice
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

This review discusses the physiology and pharmacological treatment of vertigo and related disorders. Classes of medications useful in the treatment of vertigo include anticholinergics, antihistamines, benzodiazepines, calcium channel antagonists and dopamine receptor antagonists. These medications often have multiple actions. They may modify the intensity of symptoms (e.g. vestibular suppressants) or they may affect the underlying disease process (e.g. calcium channel antagonists in the case of vestibular migraine). Most of these agents, particularly those that are sedating, also have a potential to modulate the rate of compensation for vestibular damage. This consideration has become more relevant in recent years, as vestibular rehabilitation physical therapy is now often recommended in an attempt to promote compensation. Accordingly, therapy of vertigo is optimised when the prescriber has detailed knowledge of the pharmacology of medications being administered as well as the precise actions being sought.

There are four broad causes of vertigo, for which specific regimens of drug therapy can be tailored. Otological vertigo includes disorders of the inner ear such as Ménière’s disease, vestibular neuritis, benign paroxysmal positional vertigo (BPPV) and bilateral vestibular paresis. In both Ménière’s disease and vestibular neuritis, vestibular suppressants such as anticholinergics and benzodiazepines are used. In Ménière’s disease, salt restriction and diuretics are used in an attempt to prevent flare-ups. In vestibular neuritis, only brief use of vestibular suppressants is now recommended. Drug treatments are not presently recommended for BPPV and bilateral vestibular paresis, but physical therapy treatment can be very useful in both. Central vertigo includes entities such as vertigo associated with migraine and certain strokes. Prophylactic agents (L-channel calcium channel antagonists, tricyclic antidepressants, β-blockers) are the mainstay of treatment for migraine-associated vertigo. In individuals with stroke or other structural lesions of the brainstem or cerebellum, an eclectic approach incorporating trials of vestibular suppressants and physical therapy is recommended. Psychogenic vertigo occurs in association with disorders such as panic disorder, anxiety disorder and agoraphobia. Benzodiazepines are the most useful agents here. Undetermined and illdefined causes of vertigo make up a large remainder of diagnoses. An empirical approach to these patients incorporating trials of medications of general utility, such as benzodiazepines, as well as trials of medication withdrawal when appropriate, physical therapy and psychiatric consultation is suggested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification only and does not imply endorsement.

References

  1. Baloh RW, Honrubia V. Clinical neurophysiology of the vestibular system. Contemp Neurol Ser 1979; 18: 1–21

    PubMed  CAS  Google Scholar 

  2. Takeda N, Morita M, Hasegawa S, et al. Neurochemical mechanisms of motion sickness. Am J Otolaryngol 1989; 10(5): 351–9

    Article  PubMed  CAS  Google Scholar 

  3. Takeda N, Morita M, Hasegawa S, et al. Neuropharmacology of motion sickness and emesis: a review. Acta Otolaryngol Suppl 1993; 501: 10–5

    Article  CAS  Google Scholar 

  4. Serafin M, Khateb A, Waele C, et al. In vitro properties of medial vestibular neurones. In: Shimazu H, Shinoda Y, editors. Vestibular and brain stem control of eye, head, and body movements. Basel: Karger AG, 1992: 111–21

    Google Scholar 

  5. de Waele C, Muhlethaler M, Vidal PP. Neurochemistry of the central vestibular pathways. Brain Res Brain Res Rev 1995; 20(1): 24–46

    Article  PubMed  Google Scholar 

  6. Bienhold H, Flohr H. Role of cholinergic synapses in vestibular compensation. Brain Res 1980; 195(2): 476–8

    Article  PubMed  CAS  Google Scholar 

  7. Barton JJ, Huaman AG, Sharpe JA. Muscarinic antagonists in the treatment of acquired pendular and downbeat nystagmus: a double-blind, randomized trial of three intravenous drugs. Ann Neurol 1994; 35(3): 319–25

    Article  PubMed  CAS  Google Scholar 

  8. Smith PF, Darlington CL. Pharmacology of the vestibular system. Baillieres Clin Neurol 1994; 3(3): 467–84

    PubMed  CAS  Google Scholar 

  9. Van Neerven J, Pompeiano O, Collewijn H. Depression of the vestibulo-ocular and optokinetic responses by intrafloccular microinjection of GABA-A and GABA-B agonists in the rabbit. Arch Ital Biol 1989; 127(4): 243–63

    PubMed  Google Scholar 

  10. Cohen B, Helwig D, Raphan T. Baclofen and velocity storage: a model of the effects of the drug on the vestibulo-ocular reflex in the rhesus monkey. J Physiol 1987; 393: 703–25

    PubMed  CAS  Google Scholar 

  11. Spencer RF, Wang SF, Baker R. The pathways and functions of GABA in the oculomotor system. Prog Brain Res 1992; 90: 307–31

    Article  PubMed  CAS  Google Scholar 

  12. Smith PF, Darlington CL. Recent advances in the pharmacology of the vestibulo-ocular reflex system. Trends Pharmacol Sci 1996; 17(11): 421–7

    Article  PubMed  CAS  Google Scholar 

  13. Wood CD. Antimotion sickness and antiemetic drugs. Drugs 1979; 17(6): 471–9

    Article  PubMed  CAS  Google Scholar 

  14. Petrosini L, Dell’Anna ME. Vestibular compensation is affected by treatment with dopamine active agents. Arch Ital Biol 1993; 131(2–3): 159–71

    PubMed  CAS  Google Scholar 

  15. Stott JR, Barnes GR, Wright RJ, et al. The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties. Br J Clin Pharmacol 1989; 27(2): 147–57

    Article  PubMed  CAS  Google Scholar 

  16. Okada F, Torii Y, Saito H, et al. Antiemetic effects of serotonergic 5-HT1 A-receptor agonists in Suncus murinus. Jpn J Pharmacol 1994; 64(2): 109–14

    Article  PubMed  CAS  Google Scholar 

  17. Endo T, Minami M, Hirafuji M, et al. Neurochemistry and neuropharmacology of emesis: the role of serotonin. Toxicology 2000; 153(1–3): 189–201

    Article  PubMed  CAS  Google Scholar 

  18. Kirsten EB, Schoener EP. Action of anticholinergic and related agents on single vestibular neurones. Neuropharmacology 1973; 12(12): 1167–77

    Article  PubMed  CAS  Google Scholar 

  19. Pyykko I, Schalen L, Jantti V. Transdermally administered scopolamine vs. dimenhydrinate. I: effect on nausea and vertigo in experimentally induced motion sickness. Acta Otolaryngol 1985; 99(5–6): 588–96

    Article  PubMed  CAS  Google Scholar 

  20. Pyykko I, Padoan S, Schalen L, et al. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus. Aviat Space Environ Med 1985; 56(8): 777–82

    PubMed  CAS  Google Scholar 

  21. Pyykko I, Schalen L, Matsuoka I. Transdermally administered scopolamine vs. dimenhydrinate. II: effect on different types of nystagmus. Acta Otolaryngol 1985; 99(5–6): 597–604

    Article  PubMed  CAS  Google Scholar 

  22. Shojaku H, Watanabe Y, Ito M, et al. Effect of transdermally administered scopolamine on the vestibular system in humans. Acta Otolaryngol Suppl 1993; 504: 41–5

    Article  CAS  Google Scholar 

  23. Storper IS, Spitzer JB, Scanlan M. Use of glycopyrrolate in the treatment of Meniere’s disease. Laryngoscope 1998; 108(10): 1442–5

    Article  PubMed  CAS  Google Scholar 

  24. Feder RE. Transdermal scopolamine withdrawal syndrome [letter]. Clin Neuropharmacol 1999; 22(2): 120

    Article  PubMed  CAS  Google Scholar 

  25. Padoan S, Korttila K, Magnusson M, et al. Reduction of gain and time constant of vestibulo-ocular reflex in man induced by diazepam and thiopental. J Vestib Res 1990; 1(1): 97–104

    PubMed  Google Scholar 

  26. Blair SM, Gavin M. Modifications of vestibulo-ocular reflex induced by diazepam: experiments in the macaque. Arch Otolaryngol 1979; 105(12): 698–701

    Article  PubMed  CAS  Google Scholar 

  27. McClure JA, Lycett P, Baskerville JC. Diazepam as an antimotion sickness drug. J Otolaryngol 1982; 11(4): 253–9

    PubMed  CAS  Google Scholar 

  28. Martin J, Gilchrist DP, Smith PF, et al. Early diazepam treatment following unilateral labyrinthectomy does not impair vestibular compensation of spontaneous nystagmus in guinea pig. J Vestib Res 1996; 6(2): 135–9

    Article  PubMed  CAS  Google Scholar 

  29. Funderburk FR, Griffiths RR, McLeod DR, et al. Relative abuse liability of lorazepam and diazepam: an evaluation in ‘recreational’ drug users. Drug Alcohol Depend 1988; 22(3): 215–22

    Article  PubMed  CAS  Google Scholar 

  30. Halmagyi M. Vertigo and vestibular disorders. In: Eadie MJ, editor. Drug therapy in neurology. Edinburgh: Churchill Livingstone, 1992: 375–85

    Google Scholar 

  31. Lee JA, Watson LA, Boothby G. Calcium antagonists in the prevention of motion sickness. Aviat Space Environ Med 1986; 57(1): 45–8

    PubMed  CAS  Google Scholar 

  32. Verspeelt J, De Locht P, Amery WK. Postmarketing study of the use of flunarizine in vestibular vertigo and in migraine. Eur J Clin Pharmacol 1996; 51(1): 15–22

    Article  PubMed  CAS  Google Scholar 

  33. Lassen LF, Hirsch BE, Kamerer DB. Use of nimodipine in the medical treatment of Meniere’s disease: clinical experience. Am J Otol 1996; 17(4): 577–80

    PubMed  CAS  Google Scholar 

  34. Pianese CP, Hidalgo LO, Gonzales RH, et al. New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study. Otol Neurotol 2002; 23(3): 357–63

    Article  PubMed  Google Scholar 

  35. Aoki M, Ito Y, Miyata H. Prevention of vestibular deafferentation-induced spontaneous nystagmus with pretreatment of Ca2+ channel/N-methyl-D-aspartic acid receptor antagonists in guinea pigs. Acta Otolaryngol 1998; 118(4): 554–6

    Article  PubMed  CAS  Google Scholar 

  36. Takeuchi S, Marcus DC, Wangemann P. Maxi K+ channel in apical membrane of vestibular dark cells. Am J Physiol 1992; 262 (6 Pt l):C1430–6

    PubMed  CAS  Google Scholar 

  37. Rascol O, Clanet M, Montastruc JL. Calcium antagonists and the vestibular system: a critical review of flunarizine as an antivertigo drug. Fundam Clin Pharmacol 1989; 3: 79s–87s

    Article  PubMed  Google Scholar 

  38. Rassekh CH, Harker LA. The prevalence of migraine in Meniere’s disease. Laryngoscope 1992; 102(2): 135–8

    Article  PubMed  CAS  Google Scholar 

  39. Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine: a double-blind, placebo-controlled study. JAMA 1983; 250(18): 2500–2

    Article  PubMed  CAS  Google Scholar 

  40. Grontved A, Brask T, Kambskard J, et al. Ginger root against seasickness: a controlled trial on the open sea. Acta Otolaryngol 1988; 105(1–2): 45–9

    Article  PubMed  CAS  Google Scholar 

  41. Kohl RL. Failure of metoclopramide to control emesis or nausea due to stressful angular or linear acceleration. Aviat Space Environ Med 1987; 58(2): 125–31

    PubMed  CAS  Google Scholar 

  42. Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother 1999; 33(4): 429–40

    Article  PubMed  CAS  Google Scholar 

  43. Macleod AD. Ondansetron in multiple sclerosis. J Pain Symptom Manage 2000; 20(5): 388–91

    Article  PubMed  CAS  Google Scholar 

  44. Bance M, Mai M, Tomlinson D, et al. The changing direction of nystagmus in acute Meniere’s disease: pathophysiological implications. Laryngoscope 1991; 101(2): 197–201

    Article  PubMed  CAS  Google Scholar 

  45. McClure JA, Copp JC, Lycett P. Recovery nystagmus in Meniere’s disease. Laryngoscope 1981; 91(10): 1727–37

    Article  PubMed  CAS  Google Scholar 

  46. Smith PF, Darlington CL. Can vestibular compensation be enhanced by drug treatment? A review of recent evidence. J Vestib Res 1994; 4(3): 169–79

    PubMed  CAS  Google Scholar 

  47. Crisostomo EA, Duncan PW, Propst M, et al. Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. Ann Neurol 1988; 23(1): 94–7

    Article  PubMed  CAS  Google Scholar 

  48. Torok N. Old and new in Meniere disease. Laryngoscope 1977; 87(11): 1870–7

    PubMed  CAS  Google Scholar 

  49. Ruckenstein MJ, Rutka JA, Hawke M. The treatment of Meniere’s disease: Torok revisited. Laryngoscope 1991; 101(2): 211–8

    Article  PubMed  CAS  Google Scholar 

  50. Fischer AJ. Histamine in the treatment of vertigo. Acta Otolaryngol Suppl 1991; 479: 24–8

    Article  CAS  Google Scholar 

  51. Kingma H, Bonink M, Meulenbroeks A, et al. Dose-dependent effect of betahistine on the vestibulo-ocular reflex: a double-blind, placebo controlled study in patients with paroxysmal vertigo. Acta Otolaryngol 1997; 117(5): 641–6

    Article  PubMed  CAS  Google Scholar 

  52. Botta L, Mira E, Valli S, et al. Effects of betahistine on vestibular receptors of the frog. Acta Otolaryngol 1998; 118(4): 519–23

    Article  PubMed  CAS  Google Scholar 

  53. Dziadziola JK, Laurikainen EL, Rachel JD, et al. Betahistine increases vestibular blood flow. Otolaryngol Head Neck Surg 1999; 120(3): 400–5

    Article  PubMed  CAS  Google Scholar 

  54. Colletti V. Medical treatment in Meniere’s disease: avoiding vestibular neurectomy and facilitating postoperative compensation. Acta Otolaryngol Suppl 2000; 544: 27–33

    Article  CAS  Google Scholar 

  55. James AL, Burton MJ. Betahistine for Meniere’s disease or syndrome [CD001873]. The Cochrane Database Systematic Reviews. Available in the Cochrane Library [database on disk and CD ROM]. The Cochrane Collaboration; issue 1. Oxford: Oxford Update Software, 2001

    Google Scholar 

  56. Kanigel R. Why patients take Ginkgo. Hippocrates 1999 Oct: 11-3

  57. Cesarani A, Meloni F, Alpini D, et al. Ginkgo biloba (EGb 761) in the treatment of equilibrium disorders. Adv Ther 1998; 15(5): 291–304

    PubMed  CAS  Google Scholar 

  58. Weiser M, Strosser W, Klein P. Homeopathic vs conventional treatment of vertigo: a randomized double-blind controlled clinical study. Arch Otolaryngol Head Neck Surg 1998; 124(8): 879–85

    PubMed  CAS  Google Scholar 

  59. Shiller AD, Burke DT, Kim HJ, et al. Treatment with amantadine potentiated motor learning in a patient with traumatic brain injury of 15 years’ duration. Brain Inj 1999; 13(9): 715–21

    Article  PubMed  CAS  Google Scholar 

  60. Brandt T. Vertigo: its multisensory syndromes. London: Springer-Verlag, 1991: 17,48–9

    Book  Google Scholar 

  61. Brandt T. Benign paroxysmal positioning vertigo. Adv Otorhinolaryngol 1999; 55: 169–94

    PubMed  CAS  Google Scholar 

  62. Brandt T, Daroff RB. Physical therapy for benign paroxysmal positional vertigo. Arch Otolaryngol 1980; 106(8): 484–5

    Article  PubMed  CAS  Google Scholar 

  63. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere’s disease: American Academy of Otolaryngology — Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg 1995; 113: 181-5

    Google Scholar 

  64. Brandt T, Steddin S, Daroff RB. Therapy for benign paroxysmal positioning vertigo, revisited. Neurology 1994; 44(5): 796–800

    Article  PubMed  CAS  Google Scholar 

  65. Shea Jr JJ. Classification of Meniere’s disease. Am J Otol 1993; 14(3): 224–9

    PubMed  Google Scholar 

  66. Bergenius J, Borg E. Audio-vestibular findings in patients with vestibular neuritis. Acta Otolaryngol 1983; 96(5–6): 389–95

    Article  PubMed  CAS  Google Scholar 

  67. Lacour M, Roll JP, Appaix M. Modifications and development of spinal reflexes in the alert baboon (Papio papio) following an unilateral vestibular neurotomy. Brain Res 1976; 113(2): 255–69

    Article  PubMed  CAS  Google Scholar 

  68. Furman JM, Balaban CD, Pollack IF. Vestibular compensation in a patient with a cerebellar infarction. Neurology 1997; 48(4): 916–20

    Article  PubMed  CAS  Google Scholar 

  69. Barion U, Andretta M. Compensation mechanisms after acute peripheral disorders of the labyrinth as a function of age. Acta Otorhinolaryngol Belg 1988; 42(1): 28–34

    PubMed  CAS  Google Scholar 

  70. JC. Living without a balancing mechanism. N Engl J Med 1952; 246: 458–60

    Article  Google Scholar 

  71. Hinojosa R, Nelson EG, Lerner SA, et al. Aminoglycoside ototoxicity: a human temporal bone study. Laryngoscope 2001; 111(10): 1797–805

    Article  PubMed  CAS  Google Scholar 

  72. Minor LB. Gentamicin-induced bilateral vestibular hypofunction. JAMA 1998; 279(7): 541–4

    Article  PubMed  CAS  Google Scholar 

  73. Oliveira J. Audiovestibular toxicity of drugs. Vol. II. Boca Raton (FL): CRC Press, 1989

    Google Scholar 

  74. Drachman DA, Hart CW. An approach to the dizzy patient. Neurology 1972; 22(4): 323–34

    Article  PubMed  CAS  Google Scholar 

  75. Bikhazi P, Jackson C, Ruckenstein MJ. Efficacy of antimigrainous therapy in the treatment of migraine-associated dizziness. Am J Otol 1997; 18(3): 350–4

    PubMed  CAS  Google Scholar 

  76. Diener HC, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs 1998; 56(5): 811–24

    Article  PubMed  CAS  Google Scholar 

  77. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 2001; 10(10): 1831–45

    Article  PubMed  CAS  Google Scholar 

  78. Vahedi K, Taupin P, Djomby R, et al. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial. J Neurol 2002; 249(2): 206–11

    Article  PubMed  CAS  Google Scholar 

  79. Juergens S. Alprazolam and diazepam: addiction potential. J Subst Abuse Treat 1991; 8(1–2): 43–51

    Article  PubMed  CAS  Google Scholar 

  80. Rice GP, Ebers GC. Ondansetron for intractable vertigo complicating acute brainstem disorders. Lancet 1995; 345(8958): 1182–3

    Article  PubMed  CAS  Google Scholar 

  81. Baloh RW, Winder A. Acetazolamide-responsive vestibulo-cerebellar syndrome: clinical and oculographic features. Neurology 1991; 41(3): 429–33

    Article  PubMed  CAS  Google Scholar 

  82. Averbuch-Heller L, Tusa RJ, Fuhry L, et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol 1997; 41(6): 818–25

    Article  PubMed  CAS  Google Scholar 

  83. Lawden MC, Bronstein AM, Kennard C. Repetitive paroxysmal nystagmus and vertigo. Neurology 1995; 45(2): 276–80

    Article  PubMed  CAS  Google Scholar 

  84. Afzelius LE, Henriksson NG, Wahlgren L. Vertigo and dizziness of functional origin. Laryngoscope 1980; 90(4): 649–56

    Article  PubMed  CAS  Google Scholar 

  85. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999; 20(3): 277–87

    Article  PubMed  CAS  Google Scholar 

  86. Trindade E, Menon D, Topfer LA, et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998; 159(10): 1245–52

    PubMed  CAS  Google Scholar 

  87. Kyle CJ, Petersen HE, Overo KF. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998; 8(4): 147–53

    Article  PubMed  CAS  Google Scholar 

  88. Brauer HR, Nowicki PW, Catalano G, et al. Panic attacks associated with citalopram. South Med J 2002; 95(9): 1088–9

    PubMed  Google Scholar 

  89. Ensrud KE, Blackwell TL, Mangione CM, et al. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 2002; 50(10): 1629–37

    Article  PubMed  Google Scholar 

  90. Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging 1998; 12(1): 43–53

    Article  PubMed  CAS  Google Scholar 

  91. Herr RD, Zun L, Mathews JJ. A directed approach to the dizzy patient. Ann Emerg Med 1989; 18(6): 664–72

    Article  PubMed  CAS  Google Scholar 

  92. Sloane PD. Dizziness in primary care: results from the National Ambulatory Medical Care Survey. J Fam Pract 1989; 29(1): 33–8

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review/study.

Author information

Authors and Affiliations

  1. Departments of Neurology, Otolaryngology and Physical Therapy/Human Movement Science, Northwestern University, 645 N. Michigan, Suite 1100, Chicago, Illinois, 60611, USA

    Timothy C. Hain & Mohammed Uddin

Authors
  1. Timothy C. Hain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammed Uddin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy C. Hain.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hain, T.C., Uddin, M. Pharmacological Treatment of Vertigo. Mol Diag Ther 17, 85–100 (2003). https://doi.org/10.2165/00023210-200317020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200317020-00002

Keywords

Search

Navigation